Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;81(2):145-54.
doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12.

Treatment and detection of ALK-rearranged NSCLC

Solange Peters  1 , Miquel Taron, Lukas Bubendorf, Fiona Blackhall, Rolf Stahel
Affiliations
Review

Treatment and detection of ALK-rearranged NSCLC

Solange Peters et al. Lung Cancer. 2013 Aug.

Abstract

The recent approval of crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC) in the US and other countries has provoked intense interest in ALK rearrangements as oncogenic drivers, and promises to revolutionise the way in which NSCLC is diagnosed and treated. Here, we review clinical data to date for the use of crizotinib to treat patients with advanced, ALK-positive NSCLC and consider issues surrounding the detection of ALK-positivity including the use of fluorescence in situ hybridisation and the other potential techniques available, and their suitability for ALK screening. We also discuss the emergence of resistance to crizotinib therapy and the range of other ALK inhibitors currently in development.

Keywords: ALK inhibitor; ALK rearrangement; Crizotinib; Diagnosis; NSCLC; Resistance.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources